Christopher Ngai

Christopher Ngai

Auto-generated profile, based on publicly available information

Christopher Ngai

Bayer HealthCare, Whippany, New Jersey, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Health Economics and Outcomes Research
Verified
Journal Article
Open access
PDF file
CKChristina Soeun Kwon
Christina Soeun Kwon
PDPatrick Daniele
Patrick Daniele
AFAnna Forsythe
Anna Forsythe
CNChristopher Ngai
Christopher Ngai
Introduction: This systematic literature review analyzed published evidence on IgA nephropathy (IgAN), focusing on US epidemiology, health-related quality of life (HRQoL), and economic burden of illness. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Embase®, MEDLINE®, Cochrane, and Econlit (January 2010 to June 2020) were searched, along with relevant congresses (2017-2020). Results: Of 123 epidemiologic studies selected for data extraction, 24 reported IgAN diagnosis rates ranging from 6.3% to 29.7% among adult and pediatric patients undergoing renal biopsy, with all reported US rates <15%. No US studies reported IgAN prevalence. A meta-analysis of US studies calculated an annual incidence of 1.29/100 000 people, translating to an annual US incidence of 4236 adults and children. Relative to Europe, the United States had more patients diagnosed with IgAN in later chronic kidney disease stages. US rates of transition to end-stage renal disease (ESRD) ranged from 12.5% to 23% during 3-3.9 years of observation, rising to 53% during 19 years of observation. Across 8 studies reporting HRQoL, pain and fatigue were the most reported symptoms, and patients consistently ranked kidney function and mortality as the most important treatment outcomes. Patients with glomerulopathy reported worse mental health than healthy controls or hemodialysis patients; proteinuria was significantly associated with poorer HRQoL and depression. Conclusion: While economic evidence in IgAN remains sparse, management of ESRD is a major cost driver. IgAN is a rare disease where disease progression causes increasing patient burden, underscoring the need for therapies that prevent kidney function decline and HRQoL deterioration while reducing mortality.

1 March 2023 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
LRLauren Ramjee
Lauren Ramjee
NVNesrin Vurgun
Nesrin Vurgun
CNChristopher Ngai
Christopher Ngai
MPMit Patel
Mit Patel
GTGabriel Tremblay
Gabriel Tremblay
Purpose: To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients with primary immunoglobulin A nephropathy (IgAN) from a United States (US) societal perspective. Methods: A lifetime horizon, semi-Markov model was developed that consisted of nine health states: chronic kidney disease (CKD) stage 1, 2, 3a, 3b, 4, end-stage renal disease (ESRD) with dialysis, ESRD without dialysis, post-kidney transplant, and death. Health state occupancy was estimated from individual patient-level data from the Phase 3 randomized controlled trial NefIgArd Part A (NCT03643965). Additional scenarios evaluated the impact of varying the time horizon, discounting, costs included, rounds of treatment, and the method used to calculate transition probabilities. Results: In the deterministic base case analysis over a lifetime horizon, Nefecon plus BSC (hereafter Nefecon) had an incremental cost of $3,810 vs BSC. Nefecon resulted in a mean survival gain of 0.247 quality-adjusted life years (QALYs), 0.195 life years (LYs), and 0.244 equal value life years (evLYs) vs BSC alone – this resulted in incremental cost-effectiveness ratios (ICERs) of $15,428 per QALY, $19,502 per LY, and $15,611 per evLY gained. Probabilistic sensitivity analyses estimated that with willingness to pay thresholds of $100,000, $150,000, and $250,000 per QALY gained, Nefecon would be cost-effective over BSC in 66.70%, 75.02%, and 86.82% of cases, respectively. In the scenario analysis, Nefecon remained cost-effective with 4 rounds of treatment. Conclusion: Nefecon was associated with LY and QALY gains vs BSC, with an incremental cost of $3,810. Based on these values, with a willingness to pay threshold of $100,000 per QALY gained, Nefecon was found to be a cost-effective treatment for US adults with primary IgAN.

24 June 2015 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
JWJohn Whalen
John Whalen
JCJ. Chang
J. Chang
IOI. Ozer-Stillman
I. Ozer-Stillman
AAA. Ambavane
A. Ambavane
CNC. Ngai
C. Ngai
Introduction: There is a growing concern that new, high-cost cancer treatment does not necessarily translate into improved outcomes. Several techniques have been used to evaluate the incremental cost/benefit of a new cancer treatment including complex modeling such as cost-effectiveness analysis. This analysis explores a simple, direct measure of the value (cost per month of OS gain) using targeted treatments for mCRC and cost data from France.

24 June 2015 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
JWJ. Whalen
J. Whalen
JCJ. Chang
J. Chang
IOI. Ozer-Stillman
I. Ozer-Stillman
AAA. Ambavane
A. Ambavane
CNC. Ngai
C. Ngai
Introduction: Cost-benefit analyses have been used to evaluate new targeted therapies for cancer, often relying on complex models and extrapolation of overall survival beyond clinical trial follow-up. This exploratory analysis conducts a basic cost-benefit analysis of targeted therapies in mCRC, using a Spanish perspective, based on observed survival in clinical trials.

1 December 2025 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
CNChristopher Ngai
Christopher Ngai
MPMit Patel
Mit Patel
AKAgnieszka Kopiec
Agnieszka Kopiec
SFShuai Fu
Shuai Fu
NHNoemi Hummel
Noemi Hummel
Aim: We compared the effects of nefecon, an oral targeted-release budesonide formulation, and sparsentan, an oral, dual endothelin-angiotensin receptor antagonist, on estimated glomerular filtration rate (eGFR) in patients with immunoglobulin A nephropathy, a leading cause of chronic kidney disease. Materials & methods: We conducted an anchored matching-adjusted indirect comparison (MAIC) using patient-level data from NefIgArd ( NCT03643965 ; n = 364), a randomized (1:1) trial of nefecon plus optimized renin–angiotensin system inhibitor (RASi) therapy versus placebo plus RASi; and aggregate data from PROTECT ( NCT03762850 ; n = 404), a randomized (1:1) trial of sparsentan versus irbesartan, an angiotensin receptor blocker. Mean absolute eGFR change and mean relative urine protein-to-creatinine and urine albumin-to-creatinine ratio changes from baseline at 9, 12 and 24 months (NefIgArd) or 36, 48 and 106 weeks (PROTECT) were analyzed using a mixed-effects model for repeated measures. A composite outcome (time to confirmed 40% eGFR reduction, end-stage kidney disease or all-cause mortality) was also included. An unanchored MAIC and network meta-analysis were used as sensitivity analyses. Results: The matching process reduced the effective sample for the NefIgArd trial from 364 to 208. Absolute eGFR change significantly favored nefecon over sparsentan at 9 months (mean difference, ml/min/1.73 m 2 [95% credible interval]: 5.7 [3.1–8.2]), 12 months (3.5 [1.0–6.0]) and 24 months (3.3 [0.0–6.5]). Differences in other outcomes were generally not statistically significant. Sensitivity analysis results were consistent with the main findings. Conclusion: In patients with immunoglobulin A nephropathy, nefecon plus optimized RASi may preserve kidney function to a greater extent than sparsentan.